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Abstract
Background The proinflammatory cytokine interleukin-1β (IL-1β) is
overexpressed in Alzheimer disease (AD) as a key regulator of
neuroinflammation. Amyloid-β (Aβ) peptide triggers activation of inflammasomes,
protein complexes responsible for IL-1β maturation in microglial cells.
Downregulation of NALP3 (NACHT, LRR, and PYD domains-containing protein
3) inflammasome has been shown to decrease amyloid load and rescue cognitive
deficits in a mouse model of AD. Whereas activation of inflammasome in
microglial cells has been described in AD, no data are currently available
concerning activation of inflammasome in astrocytes, although they are
involved in inflammatory response and phagocytosis. Here, by targeting the
inflammasome adaptor protein ASC (apoptosis-associated speck-like protein
containing a CARD domain), we investigated the influence of activation of the
inflammasome on the phagocytic activity of astrocytes. Methods We used an ASC
knockout mouse model, as ASC is a central ...
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Abstract
Background: The proinflammatory cytokine interleukin-1β (IL-1β) is overexpressed in Alzheimer disease (AD) as a key
regulator of neuroinflammation. Amyloid-β (Aβ) peptide triggers activation of inflammasomes, protein complexes
responsible for IL-1β maturation in microglial cells. Downregulation of NALP3 (NACHT, LRR, and PYD domains-
containing protein 3) inflammasome has been shown to decrease amyloid load and rescue cognitive deficits in a
mouse model of AD. Whereas activation of inflammasome in microglial cells has been described in AD, no data are
currently available concerning activation of inflammasome in astrocytes, although they are involved in inflammatory
response and phagocytosis. Here, by targeting the inflammasome adaptor protein ASC (apoptosis-associated speck-like
protein containing a CARD domain), we investigated the influence of activation of the inflammasome on the
phagocytic activity of astrocytes.
Methods: We used an ASC knockout mouse model, as ASC is a central protein in the inflammasome, acting as an
adaptor and stabilizer of the complex and thus critical for its activation. Lipopolysaccharide (LPS)-primed primary
cultures of astrocytes from newborn mice were utilized to evaluate Aβ-induced inflammasome activation by
measuring IL-1β release by ECLIA (electro-chemiluminescence immunoassay). Phagocytosis efficiency was measured by
incorporation of bioparticles, and the release of the chemokine CCL3 (C-C motif ligand 3) was measured by ECLIA. ASC
mice were crossbred with 5xFAD (familial Alzheimer disease) mice and tested for spatial reference memory using the
Morris water maze (MWM) at 7–8 months of age. Amyloid load and CCL3 were quantified by thioflavine S staining and
quantitative real-time polymerase chain reaction (qRT-PCR), respectively.
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Results: Cultured astrocytes primed with LPS and treated with Aβ showed an ASC-dependent production of IL-1β
resulting from inflammasome activation mediated by Aβ phagocytosis and cathepsin B enzymatic activity. ASC+/−
astrocytes displayed a higher phagocytic activity as compared to ASC+/+ and ASC −/− cells, resulting from a higher
release of the chemokine CCL3. A significant decrease in amyloid load was measured in the brain of 7–8-month-old
5xFAD mice carrying the ASC +/− genotype, correlated with an increase in CCL3 gene expression. In addition, the ASC
+/− genotype rescued spatial reference memory deficits observed in 5xFAD mice.
Conclusions: Our results demonstrate that Aβ is able to activate astrocytic inflammasome. Downregulation of
inflammasome activity increases phagocytosis in astrocytes due to the release of CCL3. This could explain why
downregulation of inflammasome activity decreases amyloid load and rescues memory deficits in a mouse model of
AD.
Keywords: Alzheimer disease, Inflammasome, ASC, Astrocytes, CCL3, amyloid-β, Phagocytosis
Background
Alzheimer disease (AD), the most common cause of de-
mentia in the elderly, is characterized by alteration of cog-
nitive functions, coexistence in the brain of senile plaques
and neurofibrillary tangles, and neuronal loss [1].
Over the past decade, deposition of amyloid-β (Aβ)
peptide in senile plaques has been shown to be the driv-
ing force of a strong and chronic inflammatory response
[2, 3], characterized by the release of proinflammatory
cytokines by reactive microglial cells and astrocytes sur-
rounding amyloid deposits. This neuroinflammation
plays a critical role in the pathogenesis of AD, by indu-
cing neuronal toxicity leading to cognitive deficits [4, 5],
but also contributes to protective mechanisms, since
glial reactivity increases phagocytosis and clearance of
Aβ deposits [6].
Interleukin-1β (IL-1β) is detected in astrocytes and
microglial cells in the brains of AD patients as well as in
animal models of AD [7–12]. Since IL-1β lacks a signal
peptide, it is produced as the inactive precursor pro-IL-
1β and requires processing by the cysteine protease
caspase-1 to be active [13, 14]. Cytosolic multiprotein
complexes called “inflammasomes” tightly control the
activity of caspase-1. The inflammasome is an oligo-
meric protein complex organized as a tripartite struc-
ture: (1) a cytosolic danger sensor from the NLR (NOD-
like receptor) family such as NALP3 (NACHT, LRR, and
PYD domains-containing protein 3) also known as
NLRP3 (NOD-like receptor family, pyrin domain con-
taining 3) and NALP1 or IPAF (ice protease-activating
factor), (2) the proteolytic effector caspase-1, and (3)
ASC (apoptosis-associated speck-like protein containing
a CARD domain), an adaptor protein needed to recruit
NLR and to stabilize caspase-1/NLR complexes [15].
It was recently demonstrated that inflammasome con-
taining NALP3 can be activated by Aβ peptide in vitro,
leading to inflammation and tissue damage [7]. More-
over, NALP3 deficiency in the APP/PS1 AD mouse
model results in a decrease in Aβ deposition and rescue
of memory deficits [16]. Although most of the studies
focused so far on the possible implication of microglial
inflammasome in AD, recent studies suggest that astro-
cytic inflammasome can also play a role. Downregulation
of astrocytic IPAF inflammasome reduces Aβ42 gener-
ation by primary neurons, and expressions of IPAF and
ASC are significantly increased in a subgroup of spor-
adic AD patients [17].
In the present study, we investigated the role of
ASC-mediated activation of the inflammasome on
phagocytic activity of astrocytes and its implication in
a mouse model of AD. We found that ASC was es-
sential for IL-1β release from primary astrocytes ex-
posed to Aβ42. Interestingly, we showed that the
heterozygous expression of ASC in ASC+/− astrocytes
was responsible for an increased phagocytic activity
linked to the release of CCL3 (C-C motif ligand 3).
In vivo, we showed, in the 5xFAD (familial Alzheimer
disease) mouse model, that heterozygous ASC expres-
sion led to a decrease in amyloid load with a rescue
of long-term spatial memory measured in the Morris
water maze (MWM).
Methods
Animals
All animal procedures used in the study were carried
out in accordance with institutional and European
guidelines as certified by Animal Ethics Committee.
ASC knockout mice on the C57Bl6/J genetic back-
ground [18] were purchased from Charles River Labora-
tory (Brussels, Belgium).
We used 5xFAD transgenic mice [19] overexpress-
ing mutant human APP695 carrying EOFAD muta-
tions K670N/M671L (Swedish) + I716V (Florida) +
V717I (London) and mutant human PS1 harboring 2
EOFAD mutations (M146L and L286V) driven by the
thymocyte differentiation antigen 1 (ThyI) promoter
(JAX Mice and Services, Bar Harbor, ME, USA).
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We crossbred hemizygous 5xFAD mice with ASC
mice. Experiments on 5xFAD ASC mice and age-
matched control were performed at 7–8 months of age.
All mice were genotyped by PCR analysis of tail biop-
sies. Animals were housed on a 12-h light/dark cycle in
standard animal care facilities with access to food and
water ad libitum.
Primary cultures of astrocytes from newborn mice and
treatments
All cell culture reagents were purchased from Invitrogen
(Carlsbad, CA). Primary glial cultures were prepared
from newborn ASC mice (P0-1). Newborn mice were
euthanized by decapitation and genotyped. The brains
were removed, and the cortico-hippocampal regions
were dissected in phosphate-buffered saline. Cells were
then mechanically dissociated in Dulbecco’s Modified
Eagle’s Medium (DMEM) (GlutaMAX)/penicillin-
streptomycin (PS, 50 mg/ml), and the supernatant was
collected and centrifuged at 280×g for 5 min. Cells were
suspended in DMEM-GlutaMAX/PS supplemented with
10 % fetal bovine serum (FBS) and PS. Cells were seeded
in 72-cm2 culture flasks and then incubated in a humidi-
fied 5 % CO2 atmosphere at 37 °C. The medium was
changed every 5 days, and cultures were maintained for
15 days.
At day 15, non-astroglial cells such as microglia and
oligodendrocytes were removed by shaking 5 h at
200 rpm/37 °C in an orbital shaker. Remaining adherent
cells were then trypsinized (trypsin-EDTA 0.05 %) and
plated at 104 cells/cm2 in appropriate non-coated wells.
Immunofluorescent staining using antibodies against
CD68 (microglia) (AbdSerotec) and GFAP (glial fibrillary
acidic protein for astrocytes) (Dako) revealed that >98 %
of cells were astrocytes.
Astroglial cultures were used at day 4 after subculture.
Cells were primed with lipopolysaccharide (LPS) from
Escherichia coli 026:B6 (Sigma-Aldrich), at 1 μg/ml for
3 h, washed with fresh medium and then treated for 3 h
with 20 μM nigericin or 10 μM Aβ42 (Bachem), previ-
ously suspended in milliQ water, incubated 72 h at 37 °C
for aggregation [20], and diluted in serum-free medium.
Cathepsin B inhibitor Ca074 at 25 μM, or 10 μM cyto-
chalasin D, was added 15 min before Aβ42.
RNA extraction, quantitative real-time PCR, and PCR
Total RNA extraction was performed according to Tri-
Pure Isolation Reagent manufacturer’s instructions
(Roche). Reverse transcription was carried out from 1 μg
of extracted RNA resuspended in DEPC-treated water,
using the iScript cDNA synthesis Kit (Bio-Rad). Quanti-
tative real-time polymerase chain reaction (qRT-PCR)
conducted with the iCycler IQTM multicolor Real-Time
PCR Detection System (Bio-Rad) was carried out from
2 ng of cDNA template, specific primers at 0.3 μM and
the IQTM SYBR® Supermix 1x. Murine primers (Sigma-
Aldrich) used for CCL3, GAPDH (glyceraldehyde 3-
phosphate dehydrogenase) and for IL-1β are presented
in the Table 1.
The PCR protocol consisted of 40 amplification cycles
with the following steps: 95 °C for 30 s, 60 °C for 45 s,
and 79 °C for 15 s. The result for each sample was nor-
malized with the relative expression of GAPDH, and
relative amplifications were calculated by the 2-ΔΔCt
method. For standard PCR, 10 μl was used and amplifi-
cation was performed using 0.125 μl of Taq DNA Poly-
merase (Thermo Fisher Scientific) and murine primers
for ASC (Table 1). Cycling was performed in a TProfes-
sional Thermocycler (Biometra), and the amplification
protocol consisted of 35 amplification cycles with the
following steps: 95 °C for 30 s, 57 °C for 1 min, and 72 °
C for 2 min. Aliquots of 8 μl of each PCR products were
loaded on a 1.2 % agarose gel with the Midori Green
Advanced DNA Stain (Nippon Genetics Europe GmbH)
as nucleic acid stain.
ECLIA
IL-1β and CCL3 were quantified in culture media from
astrocytes by ECLIA (electro-chemiluminescence im-
munoassay) on a MSD SECTORTM Imager 2400 (Meso
Scale Discovery), following manufacturer’s instructions.
The lower limit of detection (LLOD) for IL-1β was
0.6 pg/ml, whereas no LLOD was given by the manufac-
turer for CCL3 as it was a prototype kit.
Phagocytosis assay and CCL3 neutralization
Phagocytosis assay was performed following supplier’s
instructions with pHrodo™ Red Zymosan A BioParticles®
(Life Technologies) conjugate for phagocytosis. Briefly,
LPS-primed astrocytes plated in 96 wells were treated
with 10 μM Aβ42 for 3 h. Bioparticles (0.5 mg/ml) were
added 1 h after Aβ42. CCL3-neutralizing antibodies
(R&D systems) were added 15 min before bioparticles at
a concentration of 0.1 μg/ml, corresponding to the man-
ufacturer’s estimated ND50 range for CCL3-detected
Table 1 List of primers used and size of PCR products
Gene Primer sequences Size (bp)
CCL3 Forward: 5′-ATGAAGGTCTCCACCACTGC-3′ 196
Reverse: 5′-TCAGGAAAATGACACCTGGCT-3′
IL-1β Forward: 5′-ATGAAGGGCTGCTTCCAAAC-3′ 186
Reverse: 5′-GAAGGTGCTCATGTCCTCATC-3′
GAPDH Forward: 5′-ACCCAGAAGACTGTGGATGG-3′ 172
Reverse: 5′-ACACATTGGGGGTAGGAACA-3′
ASC Forward: 5′-CTAGTTTGCTGGGGAAAGAAC-3′ 394
Reverse: 5′-CTAAGCACAGTCATTGTGAGCTC-3′
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levels in our model. Primary astrocytes were also ex-
posed to mouse recombinant CCL3 (R&D systems) at
concentrations ranging from 1.5 to 10 ng/ml, to evaluate
a specific effect of the chemokine in astrocytic phago-
cytic activity. After 2 h of incubation with bioparticles,
pictures were taken using a digital inverted fluorescence
microscope (EVOS-xl; Life Technologies) with a ×4 lens.
An ECLIA for CCL3 was performed to evaluate
neutralization efficacy after LPS priming and Aβ42
treatment.
Thioflavine S staining
Mice were transcardially perfused with ice-cold PBS to
remove blood. Brains were extracted, and the right cere-
bral hemisphere was fixed by immersion in a 4 % para-
formaldehyde solution for 24 h at 4 °C. Forty
micrometer-sagittal sections were cut on a vibrating
HM650V microtome (Thermo Scientific) and were pre-
served in PBS/azide 0.1 %. Staining with thioflavin-S
(ThioS; Sigma-Aldrich), a specific β-sheet strand interca-
lant, was performed on brain sections as described pre-
viously [21]. Image acquisition was performed using a
digital inverted fluorescence microscope (EVOS-xl; Life
Technologies) with a ×4 lens. Plaques were quantified
using Image J software (U.S. National Institutes of
Health, Bethesda, MD, USA) by measuring the area of
ThioS staining in a well-defined selected area of the
hippocampus.
Behavioral analysis
The MWM with a mild learning paradigm was used for
studying spatial learning and memory. The MWM was
essentially performed as previously described [21]. Age-
matched mice (7 months old) were used. A circular
polypropylene pool (113 cm in diameter), filled with
white-opaque water (24 ± 1 °C) for hiding the submerged
escape platform (9.5 cm diameter), was used for testing.
Mice were trained to locate the hidden platform in three
trials during one training day with an inter-trial interval
of 1 h. Training over six consecutive days was per-
formed. Twenty-four hours after the last training session
on day 7, the platform was removed for a 60-s probe
trial. Mouse behavior in the pool was videotaped and
tracked using Ethovision camera and software (EthoVi-
sion 6.1 Noldus, Wageningen, The Netherlands).
Statistical analysis
The number of samples or animals is specified in the
caption for each experiments. Results are expressed as
the mean ± SEM. Statistical analysis was performed by
either one-way ANOVA with post Bonferroni multiple
comparison test or one-way ANOVA for repeated mea-
sures for the training in MWM. All analyses were per-
formed using GraphPad Prism software (GraphPad
Software Inc). Statistical significance was defined as P <
0.05.
Results
IL-1β is released by astrocytes in a cathepsin B-
dependent manner
IL-1β can be produced and released by several cell types,
including activated monocytes and macrophages, as well
as by microglial cells and astrocytes [17, 22, 23]. Recent
studies have shown that LPS-primed primary microglial
cells are able to produce IL-1β after activation of inflam-
masomes by oligomeric or fibrillar Aβ treatment [7, 24].
To assess the ability of astrocytes to produce and re-
lease IL-1β when treated with Aβ42, we used a model of
primary astrocytes from P0-1 newborn mice primed with
LPS, a TLR (Toll-like receptor) agonist, to induce a ro-
bust induction of transcription of the pro-IL-1β, as it is
not constitutively expressed. Results of qRT-PCR
showed a robust induction of pro-IL-1β after 3 h priming
with 1 μg/ml LPS, with or without Aβ42, but Aβ42 alone
did not induce any expression of pro-IL-1β (Fig. 1a),
highlighting the need of LPS priming. We confirmed
that IL-1β was secreted by primary astrocytes primed for
3 h with 1 μg/ml LPS and treated with 10 μM Aβ42 for
3 h, whereas release of IL-1β was minimal with LPS and
Aβ42 alone (Fig. 1b).
In microglial cells, the NALP3 inflammasome is
known to be activated by various toxins like nigericin,
inducing a K+ efflux, and by phagocytosis of several
crystals or aggregates (including Aβ). As astrocytes are
known to phagocytose Aβ [25], we investigated whether
Aβ-induced release of IL-1β was dependent on phago-
cytosis and subsequent release of cathepsin B from
phagolysosome.
We incubated astrocytes with 25 μM Ca074, a cathep-
sin B inhibitor, or with 10 μM cytochalasin D, 15 min
before and during Aβ treatment. We found that both cy-
tochalasin D and Ca074 were able to attenuate Aβ-
induced release of IL-1β, whereas no effect was observed
on astrocytes treated with 20 μM nigericin (Fig. 1c), in-
dicating that the induction of IL-1β by Aβ42 requires
phagocytosis and lysosomal rupture with cathepsin B
leakage in the cytosol. These observations demonstrate
that phagocytosis by astrocytes and lysosomal rupture
with cathepsin B leakage in the cytosol play an import-
ant role in the Aβ-induced maturation of IL-1β.
IL-1β release is ASC-dependent
To evaluate ASC involvement in IL-1β production by as-
trocytes, we used astroglial primary cultures from P0-1
newborn mice primed with LPS. As expected, ASC ex-
pression after LPS priming was totally abolished in ASC
−/− astrocytes and showed an intermediate level in ASC
+/− compared to ASC+/+ (Fig. 2a). High and
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comparable expressions of pro-IL-1β were observed in
LPS primed or in LPS + Aβ42 astrocytes in all geno-
types, but still, no induction was found with Aβ42 alone
(Fig. 2b). Taken together, these results demonstrate that
induction of pro-IL-1β is independent of ASC.
Release of mature IL-1β was then quantified by ECLIA
in astrocytes primed 3 h with 1 μg/ml LPS and treated
3 h with 10 μM Aβ42. Production of soluble IL-1β was
significantly decreased in ASC+/− and abolished in ASC
−/− astrocytes, indicating a specific requirement of ASC
in Aβ-induced maturation and secretion of IL-1β
(Fig. 2c).
ASC heterozygous astrocytes are more prone to
phagocytize
It is obvious that microglial cells are the immunocompe-
tent cells of the central nervous system (CNS) that dis-
play common functions with macrophages, including
phagocytosis. However, even if the role of astrocytes in
phagocytic activities is less studied, some data suggest
that they are competent phagocytes. Recent studies have
shown an Aβ-induced phagocytosis of latex beads [25]
as well as direct engulfment of Aβ [26].
We therefore investigated the phagocytic capacity of
astrocytes expressing different levels of ASC. LPS-
primed astrocytes were treated with 10 μM Aβ42 and a
highly specific phagocytosis assay was applied. It consists
in pH-sensitive-labeled yeast wall beads exhibiting fluor-
escence upon acidification of the particles as they are
ingested.
A basal phagocytic activity was observed in control
conditions. No significant increase was observed in LPS-
primed ASC+/+ and ASC−/− astrocytes treated with
Aβ42. But surprisingly, ASC+/− astrocytes showed a sig-
nificant increase in their phagocytic capacity as shown
using fluorescence microscopy (Fig. 3a) and after quanti-
fication of fluorescent areas (Fig. 3b).
These results raised the question whether such a dif-
ference could be due to an intrinsic property of ASC
heterozygous astrocytes or to a change in the release of
secreted factors. To answer that question, we exposed
ASC+/+ and ASC−/− astrocytes to medium conditioned
by ASC+/− astrocytes primed with LPS and treated with
Aβ42. In both cases, we observed a strong increase of
the phagocytic activity after exposure to ASC+/−
medium (Fig. 3c, d), indicating that the modification in
a b
c
Fig. 1 Aβ42 induces cathepsin B-dependent IL-1β release in LPS-primed astrocytes. Astrocytes primed with 1 μg/ml LPS for 3 h were treated with
10 μM Aβ42 for 3 h. Pro-IL-1β expression was determined by qRT-PCR (a) (n = 4), and IL-1β was measured by ECLIA in culture supernatants
(b) (Control and LPS n = 7 in duplicate; Aβ42 and LPS Aβ42 n = 5 in duplicate). Primed astrocytes were exposed to 20 μM nigericin or 10 μM Aβ42,
with 25 μM Ca074 or 10 μM cytochalasin D ,and IL-1β was measured by ECLIA in culture supernatants (c) (Control and LPS Nig n = 7; all others n
= 4). Results are the mean ± SEM, and statistical differences were determined using an ANOVA analysis and post Bonferroni multiple comparison
test. ***P < 0.001, **P < 0.01, and *P < 0.05
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phagocytosis efficiency resulted from a change in the
panel of released factors.
CCL3 is involved in phagocytic activity of ASC
heterozygous astrocytes
Chemokines play a critical role in phagocytic activity.
Astrocytes are characterized by expression of a panel of
chemokines including CCL3, which is expressed in mur-
ine astrocytes and binds receptors with a high affinity
[27], inducing chemotaxis in the presence of low con-
centration of ligand [28]. Moreover, astrocytes express
CCR1 and CCR5, two receptors known to bind CCL3
[29].
In astrocytes in which inflammasome was activated by
Aβ42, we measured secreted CCL3 in the culture
medium using ECLIA. We observed an increase in
CCL3 released by astrocytes from each genotype com-
pared to non-treated controls (Fig. 4a). Interestingly,
ASC +/− astrocytes showed a significant higher level of
CCL3 compared to ASC+/+ and ASC−/− astrocytes.
From these observations, we assessed phagocytic
capacity of these astrocytes following CCL3
neutralization using a specific antibody. Neutralizing
antibody was added 15 min before bioparticles, and
the culture medium was recovered at the end of the
experiment to measure CCL3 neutralization efficacy.
In each case, anti-CCL3 antibody significantly atten-
uated CCL3 detectability in culture medium of astro-
cytes (Additional file 1; ASC+/+ 72 %, ASC+/−
64 %, and ASC−/− 40 %). Phagocytic activity was
unaffected by CCL3 neutralization in ASC+/+ and
ASC−/− astrocytes but a significant 64 % decrease
was observed in ASC+/− cells (Fig. 4b, c). In order
to evaluate CCL3 effect on astrocytic phagocytosis
without the influence of other released factors, astro-
cytes were incubated in the presence of increasing
concentrations of mouse recombinant CCL3 before
measuring the incorporation of bioparticles. Results
presented in Fig. 4d, e indicate that increasing con-
centrations of CCL3 induced significant increase in
bioparticle incorporation by astrocytes, whatever
their genotype. Altogether, these results indicate that
increased secretion of CCL3 by ASC+/− astrocytes
can activate their phagocytic activity.
a
c
b
Fig. 2 Aβ42-induced IL-1β release in LPS-primed astrocytes is ASC dependent. RT-PCR with specific primers set for murine ASC and GAPDH was
performed on cDNA from astrocytes primed with 1 μg/ml LPS for 3 h (a). Pro-IL-1β expression was quantified by qRT-PCR on cDNA from astrocytes
primed with 1 μg/ml LPS for 3 h and/or treated with 10 μM Aβ42 for 3 h (b) (n = 4). The concentration of IL-1β in culture supernatants was then
measured by ECLIA (c) (Control n = 5 in duplicate; LPS Aβ42 n = 4 in duplicate for all genotypes). Results are the mean ± SEM, and statistical differences
were determined using an ANOVA analysis and post Bonferroni multiple comparison test. ***P < 0.001, **P < 0.01, and *P < 0.05 vs ASC+/+ control (b).
***P < 0.001 and **P < 0.01 vs respective controls; +++P < 0.001 and ++P < 0.01 (c)
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ac
d
b
Fig. 3 Phagocytosis is increased in ASC+/− LPS-primed astrocytes treated with Aβ42. Astrocytes primed with 1 μg/ml LPS for 3 h were treated
with 10 μM Aβ42 for 3 h. Phagocytic capacity was assessed by adding pHrodo™ Red Zymosan Bioparticles® 2 h before visualization (a); pHrodo™
Red dye conjugates fluoresce brightly red only in phagolysosomes. Media from treated ASC+/− astrocytes were added to ASC+/+ and ASC−/−
cells, and phagocytic capacity was assessed (b). Quantity of internalized bioparticles was evaluated by measuring fluorescence areas using image
J (b, d). Hoechst staining was performed to evaluate cell density. Results are expressed as a percentage of pHrodo positive area and presented as
the mean ± SEM (a, b n = 4 in duplicate; c, d n = 3 in duplicate). Statistical differences were determined using an ANOVA analysis, and post
Bonferroni multiple comparison test. **P < 0.01 and *P < 0.05 vs ASC+/− LPS Aβ42 and +++P < 0.001 vs respective control (b), **P < 0.01 vs
respective control (d)
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e
b
d
Fig. 4 (See legend on next page.)
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Decreased amyloid load in 5xFAD with heterozygous ASC
expression is correlated with increased CCL3 expression
To evaluate, in an in vivo model, the relevance of our re-
sults obtained in vitro, we crossbred hemizygous 5xFAD
with ASC knockout mice. We used 7–8 month mice as
they display a strong hippocampal amyloid deposition
and associated cognitive deficits. We focused on ASC
+/− genotype that showed an optimal phagocytic activity
in vitro.
From the in vitro results suggesting that CCL3 is crit-
ical for phagocytosis, we first assessed whether CCL3 ex-
pression was changed in 5xFAD/ASC mice. As observed
with primary culture of astrocytes, CCL3 mRNA levels
were increased in 5xFAD mice (F+ A+/+) compared to
wild-type (WT, F-A+/+), but this increase was more im-
portant in the ASC heterozygous (F+ A+/−) genotype
with an l00 % increase compared to F+ A+/+ (Fig. 5a).
In 5xFAD mice, amyloid deposits appear from
2 months of age in deep cortical layers and subiculum
and increase with age in the cortex and hippocampus
[19]. To assess the density of amyloid plaques, we
stained sagittal sections of 7–8-month-old mice with
thioflavin S and we quantified positive areas in the hip-
pocampal region (Fig. 5b, c). We found that Aβ depos-
ition was significantly reduced by about 60 % in F+ A
+/− mice compared to F+ A+/+ (Fig. 5c). Quantification
(See figure on previous page.)
Fig. 4 CCL3 release by astrocytes is ASC dependent and is critical for phagocytosis efficiency. Astrocytes primed with 1 μg/ml LPS for 3 h were treated
with 10 μM Aβ42 for 3 h. The concentration of CCL3 in culture supernatants were then measured by ECLIA (a) (Control n = 4 in duplicate; LPS Aβ42 n
= 7 in duplicate). Astrocytes were treated with 0.1 μg/ml of CCL3-neutralizing antibody 15 min before Aβ42 and phagocytic capacity was assessed by
adding pHrodo™ Red Zymosan Bioparticles® 2 h before visualization (b, c). Primary astrocytes were treated with increasing concentrations of mouse
recombinant CCL3 for 2 h during exposure to bioparticles. The amount of internalized bioparticles was evaluated by measuring fluorescence areas
using image J (c, n = 4 in duplicate; e, n = 3 in triplicate). Results are expressed as a percentage of total area and are the mean ± SEM, and statistical
differences were determined using an ANOVA analysis and post Bonferroni multiple comparison test: ***P < 0.001, **P < 0.01, and *P < 0.05 vs
respective controls (a, e), +++P < 0.001 and ++P < 0.01 (a); **P < 0.01 (c)
a
c
b
Fig. 5 Increase in CCL3 mRNA level is correlated with a decrease in amyloid load in ASC+/− 5xFAD 8-month-old mice. Expression of CCL3 was
determined by qRT-PCR on cDNA prepared from the hippocampus of 8-month-old WT and 5xFAD ASC mice. Statistical differences were determined
using an ANOVA analysis and post Bonferroni multiple comparison test. ***P < 0.001 vs all others and +++P < 0.001 (a) (5 F− A+/+, 10 F+ A+/+, and 6 F
+ A+/−). Thioflavin S staining was performed on sections from the hippocampus of 8-month-old WT and 5xFAD ASC mice (b) (7 F+ A+/+ and 4 F+ A
+/−). Amyloid plaques were quantified using image J and are represented as the mean % of total area ± SEM. Significance was assessed using an
ANOVA analysis and post Bonferroni multiple comparison test. *P < 0.05 vs all others (c)
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of the number of plaques showed the same results with
a 45 % decrease in hippocampus of F+ A+/− mice (data
not shown).
Reduced ASC expression rescues memory deficits in
5xFAD mice
Since we observed a decrease in amyloid deposition in
the hippocampus of F+ A+/− mice, we assessed
hippocampal-dependent spatial acquisition (training/
learning) and reference memory (probe trial) in these
mice using the MWM. Total path length during the
probe trial was not modified meaning that mice did not
display locomotor deficits (Additional file 2). 5xFAD
mice failed to improve significantly the latency to reach
the platform (PF) during the training period. However,
this learning deficit was rescued in F+ A+/− mice, show-
ing latency values equivalent to WT mice (Fig. 6a). F− A
+/− did not show any difference with WT mice (data
not shown).
We then tested the strength of long-term spatial mem-
ory by performing a probe trial, during which the PF has
been removed when mice are swimming for 1 min. We
used the Gallagher proximity measure (average distance
in centimeters from the center of the platform location)
[30] for the analysis of the probe trial, previously shown
to be more sensitive to group differences [31]. Results
showed a dramatic decline in long-term spatial memory
of F+ A+/+ mice as the mean distance to the PF was sig-
nificantly higher than WT mice (Fig. 6b). Nevertheless,
F+ A+/− mice were largely protected from this decline,
supporting performances observed during the training
period.
Discussion
Molecular platforms called inflammasomes are activated
upon cellular infection or stress, triggering the matur-
ation of proinflammatory cytokines such as pro-IL-1β to
engage innate immune defenses [32]. It has been shown
that aberrant inflammasome signaling contributes to
pathology in a large number of infectious and auto-
immune diseases [33]. However, their roles in CNS dis-
orders have not been extensively studied, although
recent literature suggests that inflammasomes are acti-
vated and participate to neurological diseases including
infections, acute sterile brain injury, and chronic neuro-
degenerative diseases [34].
There is a high sensitivity of the CNS to IL-1β since
multiple cerebral cell types express its receptor, which,
upon activation, potentiates proliferation and activation
of microglial cells and astrocytes [35, 36].
Previous studies have shown that the Aβ peptide of
AD can activate the NALP3 inflammasome in microglial
cells and induce release of inflammatory molecule IL-1β
in vivo and in vitro [16, 24]. Aβ-mediated inflammasome
activation in astrocytes remains, however, elusive.
In the present study, using primary culture of murine
astrocytes, we show that LPS-primed cells are able to
produce and release IL-1β under Aβ42 treatment, de-
pending on ASC expression, as ASC−/− astrocytes did
not produce significant amount of IL-1β. Activation of
inflammasome in astrocytes was recently debated, from
the absence of expression of NALP3, ASC, and caspase-
1 in astrocytes [37] to colocalization of the GFAP astro-
cytic marker with NALP3 and ASC in a murine model
of ALS [38]. We demonstrate here an activation of astro-
cytic ASC-dependent inflammasome by synthetic Aβ42,
a b
Fig. 6 Memory deficits are prevented in 5xFAD mice with ASC+/− genotype. Hippocampal-dependent learning and long-term spatial memory
were assessed in a modified Morris water maze paradigm. A protocol of three trials/day during 6 days was used as a training period for WT and
5xFAD ASC mice. Results are expressed as the mean latency to reach the platform ± SEM and analyzed by ANOVA for repeated measures, ***P <
0.001 vs F+ A+/+, (a). Probe trial was performed on day 7, and results are expressed as the mean distance to the platform (Gallagher proximity
coefficient) ± SEM, and statistical differences were determined using a ANOVA analysis and post Bonferroni multiple comparison test, **P < 0,01 vs
F− A+/+, ++P < 0.01 vs F+ A+/− (b) (15 F− A+/+, 14 F+ A+/+, and 11 F+ A+/−)
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confirming thereby that, as microglial cells, astrocytes
are able to produce IL-1β.
Phagocytosis of Aβ fibrils by macrophages or microglial
cells was proposed to be the first step for the formation of
the inflammasome complex, due to a leakage of cathepsin
B from lysosomes into the cytosol [7]. Using cytochalasin
D to inhibit phagocytosis or cathepsin B inhibitor, we
show a strong attenuation of IL-1β release, indicating that
Aβ42 triggers inflammasome activation through a lyso-
somal pathway, as is the case for microglial cells or macro-
phages. The mechanisms by which cathepsin B can
activate the inflammasome are not clear. It was recently
suggested that the Aβ-mediated release of cathepsin B
leads to the degradation of the anti-inflammatory protein
NLRP10 involved in inhibition of formation of the NALP3
inflammasome by interacting with ASC. Degradation of
NLRP10 allows ASC-NALP3 interaction, caspase-1 activa-
tion, and IL-1β release [39].
As microglial cells, astrocytes express many potential
phagocytic receptors in the CNS, like RAGE, CD36, or
TLRs, known to have Aβ among their ligands [40]. But
the role of astrocytes as phagocytic cells is less studied,
particularly in AD. Addition of astrocytes on brain sec-
tions prepared from an AD mouse model decreases Aβ
levels [26]. In APPswe/PS1dE9 mice, internalization of
Aβ was observed in transplanted astrocytes [41]. These
data confirm the role of astrocytes in amyloid clearance.
In the present study, we measured phagocytosis by
astrocytes using fluorescent bioparticles. We show an
increase in phagocytosis by ASC heterozygous astro-
cytes primed by LPS and treated with Aβ42. This in-
crease was explained by the secretion of soluble
factors since exposure of naive ASC+/+ or ASC−/−
astrocytes to conditioned medium from ASC+/− cells
induced an increase in phagocytosis.
Chemokines are critical inflammatory molecules inducing
recruitment of responsive cells such as monocytes/macro-
phages, microglia, or astrocytes. Among them, CCL3, a CC
chemokine, is known to bind receptors on murine astro-
cytes with a high affinity, stimulating chemotaxis. Three re-
ceptors are known to bind CCL3, and CCR1 and CCR5 are
expressed at the membrane of astrocytes [29]. Therefore,
we measured secretion of CCL3 in astrocytes in which
inflammasome was activated by Aβ. Increase in CCL3 re-
lease was observed in all genotypes, with significantly
higher levels with ASC+/− cells compared to ASC+/+ and
ASC−/−. It was previously reported that astrocytes produce
high amount of several chemokines and particularly CCL3
under stimulation by a mix of IL-1β and TNFα [42]. In our
model, there was an inverse correlation between TNFα and
IL-1β secretion (Additional file 3). Consequently, co-
secretion of bothTNFα and IL-1β is optimal in ASC+/− as-
trocytes, resulting in higher CCL3 production in these cells.
It is important to notice that CCL2, another chemokine
known to be produced by astrocytes, was expressed at a
very high level in control condition and thus displayed a
low rate of increase after cytokine stimulation. On the other
hand, ASC downregulation using siRNA or shRNA has
been shown to reduce MAPK pathway activation in the
THP1 cell line [43] and to activate NF-κB in murine mac-
rophages [44]. Modifications in activation of these path-
ways, known to be involved in the expression of cytokines
and chemokines, could also contribute to modulation of
the inflammatory environment.
Neutralization of released CCL3 by a specific neu-
tralizing antibody induced a significant decrease in
phagocytic activity of ASC+/− astrocytes. Moreover,
treatment of astrocytes with mouse recombinant
CCL3 alone induced a significant increase of astro-
cytic phagocytosis in each ASC genotype. Involvement
of CCL3 in the phagocytic activity of various cell
types, including macrophages, has been demonstrated.
Macrophages stimulated with recombinant CCL3 dis-
played an increase phagocytic index against Pseudo-
monas aeruginosa [45]. Moreover, phagocytic activity
of alveolar macrophages from CCL3−/− mice toward
Klebsiella pneumoniae was dramatically decreased
[46]. In vivo, CCL3 KO mice or WT mice treated
with anti-CCL3 monoclonal antibodies were more
prone to sepsis, suggesting a significant protective
role for CCL3 [45].
We extended our analysis in vivo by crossing the
very well-known 5xFAD mouse model with ASC de-
ficient mice. Interestingly, we observed a very signifi-
cant increase in CCL3 mRNA levels in the brain of
FAD/ASC heterozygous mice as compared to FAD/
WT mice. In addition, a significant decrease in
amyloid plaques was observed in FAD/ASC heterozy-
gous mice at 7–8 months of age, with a concomitant
rescue of long-term memory deficits. These results
are in line with the study of Heneka et al. [16]
showing the same effects in APPswe/PS1dE9 mice
KO for NALP3. It is important to notice that
NALP3 KO mice displayed a 50 % decrease in IL-1β
production, corresponding to our in vitro situation
in ASC+/− astrocytes. It seems, however, that high
levels or minimal production of IL-1β, as observed
in ASC+/+ and ASC−/− astrocytes could decrease
their phagocytic activity.
Conclusions
Since the first study showing an activation of the NALP3
inflammasome by Aβ and its involvement in tissue dam-
age in AD, others reports confirmed the deleterious ef-
fect of inflammasome-mediated inflammation. Here, by
targeting a central component of the inflammasome pro-
tein complex, we demonstrate a beneficial effect of ASC
downregulation on amyloid load and memory
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performances. We demonstrate in vitro that Aβ is able
to activate astrocytic inflammasome. These astrocytes
seemed to be potent actors in the clearance of amyloid
peptide, and ASC heterozygous cells displayed a higher
phagocytic efficiency when activated by Aβ. Thus, target-
ing inflammasome activation in particular in astrocytes
seems to be an interesting strategy to fight against
amyloid-induced pathological features observed in an
AD mouse model.
Additional files
Additional file 1: Neutralization of CCL3 by a specific antibody.
Astrocytes primed with 1 μg/ml LPS for 3 h were treated with 10 μM
Aβ42 for 3 h. Specific antibody against CCL3 was added 45 min after
Aβ42. The concentration of CCL3 in culture supernatants was then
measured by ECLIA. Results are the mean ± SEM derived from three
experiments in duplicate, and statistical differences were determined
using a Mann-Whitney test. ***P < 0.001, **P < 0.01, and *P < 0.05 vs
respective controls.
Additional file 2: Path length (cm) measured during the probe trial
in the Morris water maze (MWM). Mice were let in the MWM for a
1-min free swimming test. Total distances traveled were quantified and
showed no difference between all tested groups (15 F− A+/+, 14 F+ A
+/+, and 11 F+ A+/−).
Additional file 3: TNFα varies in inverse proportion to IL-1β.
Astrocytes primed with 1 μg/ml LPS for 3 h were treated with 10 μM
Aβ42 for 3 h. The concentration of TNFα or IL-1β released in culture
supernatants were then measured by specific ECLIA. Results are the
mean ± SEM, and statistical differences were determined using an ANOVA
analysis and post Bonferroni multiple comparison test (n = 4 in duplicate).
***P < 0.001, **P < 0.01, and *P < 0.05 (n = 4 in duplicate for all
genotypes).
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